Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure- based virtual screening

被引:27
|
作者
Atatreh, Noor [1 ]
Ghattas, Mohammad A. [1 ]
Bardaweel, Sanaa K. [2 ]
Al Rawashdeh, Sara [1 ]
Al Sorkhy, Mohammad [1 ]
机构
[1] Al Ain Univ Sci & Technol, Dept Pharmaceut Sci, Coll Pharm, Al Ain, U Arab Emirates
[2] Univ Jordan, Dept Pharmaceut Sci, Sch Pharm, Amman 11942, Jordan
来源
关键词
protein-protein interaction; virtual screening; Mdm2; p53; anticancer; docking; pharmacophore; ELISA; P53-MDM2; INTERACTION; P53; PATHWAY; CANCER; DISCOVERY; DESIGN; POTENT;
D O I
10.2147/DDDT.S182444
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The tumor suppressor protein p53 plays an important role in preventing tumor formation and progression through its involvement in cell division control and initiation of apoptosis. Mdm2 protein controls the activity of p53 protein through working as ubiquitin E3 ligase promoting p53 degradation through the proteasome degradation pathway. Inhibitors for Mdm2-p53 interaction have restored the activity of p53 protein and induced cancer fighting properties in the cell. Purpose: The objective of this study is to use computer-aided drug discovery techniques to search for new Mdm2-p53 interaction inhibitors. Methods: A set of pharmacophoric features were created based on a standard Mdm , inhibitor and this was used to screen a commercial drug-like ligand library; then potential inhibitors were docked and ranked in a multi-step protocol using GLIDE. Top ranked ligands from docking were evaluated for their inhibition activity of Mdm2-p53 interaction using ELISA testing. Results: Several compounds showed inhibition activity at the submicromolar level, which is comparable to the standard inhibitor Nutlin-3a. Furthermore, the discovered inhibitors were evaluated for their anticancer activities against different breast cancer cell lines, and they showed an interesting inhibition pattern. Conclusion: The reported inhibitors can represent a starting point for further SAR studies in the future and can help in the discovery of new anticancer agents.
引用
收藏
页码:3741 / 3752
页数:12
相关论文
共 50 条
  • [21] Small molecule inhibitors of the human MDM2-p53 interaction as anticancer agents
    Wang, S.
    Shangary, S.
    Qin, Q.
    McEachern, D.
    Ding, K.
    Nikolovska-Coleska, Z.
    Lu, Y.
    Malek, S.
    Guo, M.
    Yang, D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 83 - 83
  • [22] Novel inhibitors of the MDM2-p53 interaction featuring carboxylic acid isosteres
    Gonzalez, Ana Z.
    Li, Zhihong
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Duquette, Jason
    Eksterowicz, John
    Fox, Brian M.
    Fu, Jiasheng
    Huang, Xin
    Houze, Jonathan
    Jin, Lixia
    Li, Yihong
    Ling, Yun
    Lo, Mei-Chu
    Long, Alexander M.
    Mcgee, Lawrence R.
    McIntosh, Joel
    Oliner, Jonathan D.
    Osgood, Tao
    Rew, Yosup
    Saiki, Anne Y.
    Shaffer, Paul
    Wortman, Sarah
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Olson, Steven H.
    Sun, Daqing
    Medina, Julio C.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [23] Discovery of AM-8553: Structure-based design of novel piperidinone inhibitors of the MDM2-p53 interaction
    Rew, Yosup
    Sun, Daqing
    De Turiso, Felix Gonzalez Lopez
    Bartberger, Michael D.
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Deignan, Jeffrey
    Fox, Brian M.
    Gustin, Darin
    Huang, Xin
    Jiang, Min
    Jiao, Xianyun
    Jin, Lixia
    Kayser, Frank
    Kopecky, David J.
    Li, Yihong
    Lo, Mei-Chu
    Long, Alexander M.
    Michelsen, Klaus
    Oliner, Jonathan D.
    Osgood, Tao
    Ragains, Mark
    Saiki, Anne Y.
    Schneider, Steve
    Toteva, Maria
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Medina, Julio C.
    Olson, Steven H.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [24] Targeting the MDM2-p53 interaction for cancer therapy
    Shangary, Sanjeev
    Wang, Shaomeng
    CLINICAL CANCER RESEARCH, 2008, 14 (17) : 5318 - 5324
  • [25] Total Mutagenesis and the Effects on the MDM2-p53 Interaction
    Beyer, George
    Thayer, Kelly
    FASEB JOURNAL, 2015, 29
  • [26] NEW PLAYERS IN CANCER THERAPEUTICS: FOCUS ON INHIBITORS OF MDM2-P53 PROTEIN-PROTEIN INTERACTION
    Capdevila, J.
    Cervantes, A.
    Tabernero, J.
    DRUGS OF THE FUTURE, 2012, 37 (04) : 273 - 281
  • [27] Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors
    Wurz, Ryan P.
    Cee, Victor J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (02) : 445 - 447
  • [28] Troxerutin subdues hepatic tumorigenesis via disrupting the MDM2-p53 interaction
    Thomas, Nisha Susan
    George, Kiran
    Selvam, Athavan Alias Anand
    FOOD & FUNCTION, 2018, 9 (10) : 5336 - 5349
  • [29] Identification of a p53-based portable degron based on the MDM2-p53 binding region
    Melvin, Adam T.
    Dumberger, Lukas D.
    Woss, Gregery S.
    Waters, Marcey L.
    Allbritton, Nancy L.
    ANALYST, 2016, 141 (02) : 570 - 578
  • [30] Selective and Potent Morpholinone Inhibitors of the MDM2-p53 Protein-Protein Interaction
    Gonzalez, Ana Z.
    Eksterowicz, John
    Bartberger, Michael D.
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Duquette, Jason
    Fox, Brian M.
    Fu, Jiasheng
    Huang, Xin
    Houze, Jonathan B.
    Jin, Lixia
    Li, Yihong
    Li, Zhihong
    Ling, Yun
    Lo, Mei-Chu
    Long, Alexander M.
    McGee, Lawrence R.
    McIntosh, Joel
    McMinn, Dustin L.
    Oliner, Jonathan D.
    Osgood, Tao
    Rew, Yosup
    Saiki, Anne Y.
    Shaffer, Paul
    Wortman, Sarah
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Olson, Steven H.
    Medina, Julio C.
    Sun, Daqing
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (06) : 2472 - 2488